Undergoing Stem Cell Transplant for Sickle Cell Disease in Childhood
Transplant recipients show better physical, school, and social functioning than those receiving transfusions and medications alone LBA-5: Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Co...
Read moreAdding Tafasitamab Cuts Risk of Disease Progression
Patients on tafasitamab had a 57% improvement in progression-free survival compared to the control arm LBA-1: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase III Study (inMIND) (SAN D...
Read moreStem Cell Transplant Offers No Additional Benefit
Transplant shows no difference in overall or progression-free survival compared with maintenance therapy alone LBA-6: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Co...
Read moreGenetic Profile Correlates with Better Response
Variants could serve as biomarker to inform prognosis or guide treatment decisions LBA-4: Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (E...
Read moreASH Identifies Strategies and Barriers for Implementing DEI in Clinical Trials
Surveys and focus groups find little integration of DEI principles, yield actionable recommendations (SAN DIEGO, Dec. 9, 2024) — The American Society of Hematology (ASH) leveraged its convening power to launch an initiative for identifying ba...
Read moreASH Newborn SCD Screening Program in Sub-Saharan Africa Found Feasible
Program is implementable and scalable despite resource and disease burden challenges (SAN DIEGO, Dec. 8, 2024) — A multi-country newborn screening program for sickle cell disease (SCD) in sub-Saharan Africa proved feasible despite resource cons...
Read moreStudies Highlight Progress in Preventing and Treating Blood Cancers and Pre-Cancerous Conditions
Advances across continuum of care show promise and hope for patients (SAN DIEGO—Dec. 8, 2024) — Studies being presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition highlight progress in preventing and...
Read moreUniversal Duffy Testing
Study establishes groundwork for understanding the cost-effectiveness of neutrophil testing (SAN DIEGO, Dec. 7, 2024) — Universal testing for Duffy status for toddlers ages 9-12 months can be a potentially cost-effective intervention for the U.S. po...
Read moreDisease Modifying Therapies Remain Underused in SCD Despite Safety and Efficacy
ASH Research Collaborative study finds that only one-quarter of patients living with SCD are prescribed a DMT (SAN DIEGO, December 7, 2024) — Disease-modifying therapies (DMTs), particularly newer ones, for sickle cell disease (SCD) are substantia...
Read moreResearch Shows How Lifestyle Factors and Diet Affect Hematologic Care
Studies highlight interactions among lifestyle factors, disease development, and response to treatment (SAN DIEGO—Dec. 7, 2024) — Five studies presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition reveal new lin...
Read more- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission